Close menu




NOVO NORDISK A/S

Photo credits: pixabay.com

Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

  • Evotec
  • Vidac Pharma
  • Novo Nordisk
  • Drug discovery
  • Biotech
  • Pharma
  • Cancer
  • Oncology
  • Warburg effect
  • Obesity
  • Diabetes
  • Weight-loss pill

Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

Read

Commented by Carsten Mainitz on November 10th, 2026 | 05:45 CET

Exciting pharma duel: Who will take off now - BioNxt Solutions, Bayer or Novo Nordisk?

  • Pharma
  • Biotech
  • Innovations
  • Diabetes

New active ingredients, expanded indications and more user-friendly dosage forms are driving momentum in the global pharmaceutical market. BioNxt Solutions is focusing on novel oral dissolvable films and working towards regulatory and clinical breakthroughs. Industry heavyweights Bayer and Novo Nordisk have recently reported solid quarterly results. Bayer has already overcome several challenges and raised its outlook. At the same time, Novo Nordisk is impressively demonstrating how innovative forms of administration in obesity treatment can achieve soaring commercial success. Where do the most attractive opportunities for investors lie following the latest developments?

Read

Commented by Nico Popp on November 9th, 2026 | 23:05 CET

Billion-dollar opportunity in cardiac therapy: Cardiol Therapeutics, Kiniksa and Novo Nordisk

  • Pericarditis
  • Cardiovascular diseases
  • Biotech

Created and Published on Behalf of Cardiol Therapeutics

The treatment of inflammatory heart diseases is becoming one of the most lucrative segments of the pharmaceutical industry. The only drug approved to date for recurrent pericarditis is expected to exceed USD 1 billion in revenue this year. While established industry heavyweights generate enormous revenues from injectable biologics, emerging biotechnology companies are preparing the next stage of development. The focus is on the search for oral therapies intended to open up access to treatment for a much broader patient population.

Read

Commented by Lars Winter on November 9th, 2026 | 05:30 CET

Good News for Rising Share Prices: Almonty Supplies Tungsten Worldwide, Novo Nordisk Raises Guidance, Apple Heads into Christmas with Record Results

  • Almonty Industries
  • Sangdong mine
  • Tungsten
  • Tungsten production
  • critical raw materials
  • Raw materials supply
  • South Korea
  • Tungsten futures
  • Novo Nordisk
  • Wegovy pill
  • Obesity drugs
  • Forecast upgrade
  • Apple
  • iPhone
  • Quarterly results
  • Christmas trading
  • Stock check

The Sangdong mine in South Korea is producing tungsten again after more than 30 years. For raw materials specialist Almonty, this marks the start of the phase in which a strategically important deposit is set to become a reliable profit generator. This gives the share significant upside potential. At Novo Nordisk, the new Wegovy weight-loss pill is boosting business, and Apple is heading into the Christmas trading season with a record quarter. The good news should soon lead to rising share prices too. In our stock review, we examine the opportunities and the risks and take a closer look at three promising stocks.

Read

Commented by Fabian Lorenz on November 6th, 2026 | 05:31 CET

BASF Keeps Up the Pressure on Evonik! Novo Nordisk Makes a Comeback! Is Strategic Resources Next?

  • raw materials
  • steel industry
  • chemicals
  • pharma

A 25% share price gain and a year-high for BASF shares. The increase in the purchase price for Evonik cannot dampen investors' buying appetite. While the Ludwigshafen-based company is not letting up on Evonik, it is divesting parts of the group. Strategic Resources shares are a candidate for a comeback. To reduce CO₂ emissions, the steel industry is turning to electric arc furnaces. This threatens to cause shortages of high-quality iron ore pellets. Strategic Resources plans to supply these in the future. The shares have recently fallen sharply and offer an enticing entry point. At Novo Nordisk, the comeback is already under way. After a challenging year with profit warnings and a massive share price slump, there is finally positive news again. For a change, the full-year guidance was raised, not lowered. What do analysts say?

Read

Commented by Armin Schulz on November 4th, 2026 | 05:33 CET

Stocks for Healthier Harvests – Novo Nordisk, MustGrow Biologics and Nestlé at the Intersection of Appetite and Agriculture

  • Novo Nordisk
  • MustGrow Biologics
  • Nestle
  • Obesity
  • Diabetes
  • healthy living
  • organic farming
  • Mustard extract
  • Biofertiliser
  • Biological crop protection
  • Health Science
  • Food supplements

Created and published on behalf of MustGrow Biologics Corp.

Living a healthier life today also means managing one's appetite medically. People who lose weight change their eating habits and pay closer attention to where their food comes from. This brings agricultural land into focus, as it is there that the foundations are laid for producing healthy crops for consumers. At the end of October, a provider of biological crop protection products reported successful field trials in Europe. At the end of the value chain is the food group that turns harvested crops into products for health-conscious consumers. We therefore take a closer look at Novo Nordisk, MustGrow Biologics and Nestlé.

Read

Commented by André Will-Laudien on November 2nd, 2026 | 05:43 CET

The Biotech breakout: Bayer and Eli Lilly flex their muscles - are Novo Nordisk, Evotec and BioNxt the next winners?

  • BioTech
  • Pharma
  • Active ingredients
  • Oncology
  • Drug developers

That was a week of selling on the NASDAQ! The technology index lost a full 5% in its renewed attempt to exceed the 30,000-point mark. Chip stocks, which had previously performed excellently, came under considerable pressure, followed by subdued figures from Alphabet, Microsoft and, most recently, Intel. The result was hefty double-digit losses; this sector has not seen this much uncertainty in a long time. Things are very different in the biotech sector. At 7,319 points, the underlying NASDAQ Biotech Index only narrowly missed its all-time high of 7,458 points. Leading players such as Bayer and Eli Lilly brought a breath of fresh air to the sector, which could now significantly outperform other industries towards the end of the year. We take a closer look at some of the protagonists.

Read

Commented by André Will-Laudien on October 29th, 2026 | 05:39 CET

Life Sciences in Focus as Sector Rotation Takes Shape: Bayer, Vidac Pharma, Eli Lilly, Novo Nordisk and Evotec in 2027

  • BioTech Pharma
  • Drug Development
  • Drug Discovery
  • Cancer Therapy

AI is consolidating, and the Life Sciences sector is firing up its first turbo: Rising healthcare spending, the demographic ageing wave and a veritable wave of innovation are catapulting the industry straight into a multi-year supercycle – and now the major players are reallocating their capital. AI and high-tech have delivered their returns, and now the new outperformers for 2027 are stepping into the spotlight. The catch: after years of heavy losses, most stocks are trading close to their 5-year lows. That will not last! Some companies are already waiting in the wings, with the painful restructuring completed. Leading the way, Novo Nordisk continues its relentless advance as the undisputed flagship of the global obesity and diabetes wave. A genuine hidden gem for return hunters is Vidac Pharma. Through its research into the Warburg effect, the biotech firm is revolutionising cancer therapy and, as a classic high-beta play, adds a dash of spice to opportunity-focused portfolios. The giant Bayer is also back, consistently using the current valuation lull as a major entry opportunity to ignite the next phase of growth with a revamped pipeline. The power quartet is completed by Hamburg-based drug discovery company Evotec, which benefits directly from demand for complex therapies as an indispensable infrastructure and development partner. Those who want to stay ahead in the coming Life Sciences boom need to set the course for their portfolio now!

Read

Commented by Matthias Schomber on October 28th, 2026 | 05:33 CET

Targeting Billion-Dollar Markets: Why Novo Nordisk, Airbus and HPQ Silicon Offer Surprising Opportunities Despite Headwinds

  • rechargeable battery
  • battery
  • drones
  • aircraft
  • airbus
  • air
  • weight-loss injection

Created and Published on Behalf of HPQ Silicon
The stock market has been highly turbulent throughout the year. Consider the hype around memory and chip stocks. Other sectors, such as real estate, have been hit hard by high interest rates and talk of potential expropriations in Berlin. Backing the wrong horse can quickly prove costly. This autumn's market environment is once again testing investors' nerves. The wars in Ukraine and Iran, high oil prices, riots in Paris, Milan, Tirana and other cities, and surging bond yields in countries such as France continue to fuel uncertainty. While weight-loss specialist Novo Nordisk fights to defend market share and deliver fresh clinical successes, aerospace group Airbus faces the mammoth task of a record-breaking year-end push. Meanwhile, silicon pioneer HPQ Silicon is waiting in the wings for its moment in the spotlight. Its shares could be approaching a technical turning point. Our analysis examines the key figures, outlines the risks and, above all, highlights the opportunities these three exciting stocks offer.

Read

Commented by Armin Schulz on October 27th, 2026 | 05:21 CET

Pharma Stocks with a Future: Bayer, BioNxt Solutions and Novo Nordisk Expand Their Pipelines

  • Bayer
  • BioNxt Solutions
  • Novo Nordisk
  • Investments
  • Active ingredients
  • Dosage forms
  • Thin film
  • Orally disintegrating film
  • Cladribine
  • Diabetes
  • Obesity
  • Weight-loss pill

No pharmaceutical company can rely on its bestsellers forever. Eventually, patent protection expires, generic manufacturers enter the market, and margins come under pressure. Companies that fail to replenish their product pipelines risk being left behind. That is why substantial sums are currently flowing into new active ingredients, manufacturing facilities and innovative drug delivery methods. Bayer plans to invest USD 2.2 billion in a pharmaceutical plant in Ohio. Smaller developers such as BioNxt Solutions are exploring new formulations and delivery methods for established active ingredients. At the end of September, Novo Nordisk agreed to license an oral drug candidate, including an upfront payment of USD 300 million. We take a closer look at Bayer, BioNxt Solutions and Novo Nordisk.

Read